Aether Industries Limited (NSE: AETHER, BSE: 543534) is a Surat, Gujarat-based company in the Pharmaceutical Contract Manufacturing Services industry. With a market capitalisation of ₹21,710 Cr, it ranks #356 by market cap among the 6,197 Indian listed companies on FinBizNet, and #2 of 26 in Pharmaceutical Contract Manufacturing Services. At ₹1,682.10 (as of 16 Nov 2026), the share price is 7.3% below its 52-week high of ₹1,814.10 and 110.1% above its 52-week low of ₹800.45. The share price is up 127.8% over one year and up 6.1% over three months.
| Current Price | ₹1,682.10 |
|---|---|
| Market Cap | ₹21,710 Cr |
| NSE Symbol | AETHER |
| BSE Code | 543534 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | 101.8 |
| Return on Equity | 9.81% |
| Return on Assets | 6.36% |
| 52-Week Range | ₹800.45 – ₹1,814.10 |
| 1-Year Price Change | +127.8% |
| 3-Month Price Change | +6.1% |
| Beta (1Y) | 0.19 |
| Headquarters | Surat, Gujarat |
| Website | www.aether.co.in |
| Revenue | ₹347 Cr |
|---|---|
| Net Profit | ₹68 Cr |
| Net Margin | 19.6% |
| EPS (Basic) | ₹5.12 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Aether Industries Limited reported revenue of ₹347 Cr in Q2 FY27, up 26.2% from ₹275 Cr in Q2 FY26 and up 6.3% from ₹327 Cr in Q1 FY27. It posted a net profit of ₹68 Cr for the quarter, against a net profit of ₹54 Cr in Q2 FY26 (up 26.0%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹240 Cr (Q4 FY25) to ₹347 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹347 Cr | ₹68 Cr | 19.6% |
| Q1 FY27 | ₹327 Cr | ₹63 Cr | 19.2% |
| Q4 FY26 | ₹305 Cr | ₹54 Cr | 17.7% |
| Q3 FY26 | ₹317 Cr | ₹64 Cr | 20.3% |
| Q2 FY26 | ₹275 Cr | ₹54 Cr | 19.6% |
| Q1 FY26 | ₹256 Cr | ₹47 Cr | 18.4% |
| Q4 FY25 | ₹240 Cr | ₹50 Cr | 20.9% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 74.92% of Aether Industries Limited's shares as of Sept 2026, against 75.00% in Sept 2025 (−0.08 percentage points). Delivery averaged 43.7% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Aether Industries Limited produces and sells advanced intermediates and specialty chemicals in India and internationally. It also large-scale manufacturing, contract research and manufacturing services, as well as contract/exclusive manufacturing services. The company serves its products to the chemical industry, including multinational, regional, and domestic companies in the pharmaceuticals, agrochemicals, materials science, textiles, coatings, high-performance photography, additives, and oil and gas industries. It also exports its products. Aether Industries Limited was incorporated in 2013 and is headquartered in Surat, India.
1. Contract Manufacturing-This segment engages in the contract manufacturing of specialty chemicals and intermediates. 2. Contract Research and Manufacturing Services (CRAMS)-This segment provides contract research and manufacturing services. 3. Others-0 4. Large Scale Manufacturing-This segment manufactures specialty chemicals and intermediates.
1. Contract/Exclusive Manufacturing-46.3% 2. Large Scale Manufacturing-43.2% 3. CRAMS-9.2% 4. Others-1.3%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Torrent Pharma Ltd. | ₹1,79,494 Cr | 73.6 | 16.98% | ₹4,979 Cr | +30.4% |
| Aether Industries Limited | ₹21,710 Cr | 101.8 | 9.81% | ₹347 Cr | +127.8% |
| Alivus Life Sciences Ltd | ₹17,862 Cr | 31.5 | 18.36% | ₹682 Cr | +64.0% |
| Aarti Pharmalabs Ltd | ₹8,374 Cr | 52.5 | 8.49% | ₹610 Cr | +15.4% |
| Solara Active Pharma Sciences Limited | ₹3,225 Cr | n/m | -0.63% | ₹417 Cr | +22.1% |
| Sai Parenteral's Limited | ₹2,235 Cr | 115.8 | 2.88% | ₹195 Cr | — |
| KRM Ayurveda Limited | ₹521 Cr | 25.9 | 17.54% | ₹32 Cr | — |
| Trident Lifeline Limited | ₹511 Cr | 26 | — | — | +37.6% |
| Infinium Pharmachem Limited | ₹436 Cr | 36.4 | 10.54% | — | +11.7% |
Listed by market capitalisation. Ratios are shown for context only.
Aether Industries Limited is trading at ₹1,682.10, with a market capitalisation of ₹21,710 Cr.
Aether Industries Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Aether Industries Limited has a P/E of 101.8 and a return on equity of 9.81%.
Aether Industries Limited is listed on the NSE under the symbol AETHER and on the BSE under the scrip code 543534.
Aether Industries Limited's share price is up 127.8% over one year and up 6.1% over three months. Its 52-week range is ₹800.45 to ₹1,814.10.
In Q2 FY27, Aether Industries Limited reported revenue of ₹347 Cr and net profit of ₹68 Cr, with basic EPS of ₹5.12 (consolidated, parsed from the company's exchange filing).
Aether Industries Limited reported revenue of ₹347 Cr in Q2 FY27, up 26.2% from ₹275 Cr in Q2 FY26 and up 6.3% from ₹327 Cr in Q1 FY27.
Promoters held 74.92% of Aether Industries Limited's shares as of Sept 2026, against 75.00% in Sept 2025 (−0.08 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.